International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema
A Phase II/III, Double-Blind, Randomized, Placebo-Controlled, Multicenter, International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema
Sponsor: Kamada, Ltd.
A PHASE2/PHASE3 clinical study on Emphysema, this trial is completed. The trial is conducted by Kamada, Ltd. and has accumulated 6 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Dec 2019 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
-
Jun 2018 — Dec 2019 [monthly]
Completed PHASE2_PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2_PHASE3
First recorded
Dec 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Kamada, Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Birmingham, United Kingdom , Dublin, Ireland , Edinburgh, United Kingdom , Hellerup, Denmark , Homburg/Saar, Germany , Leiden, Netherlands , London, United Kingdom , Malmo, Sweden , Marburg, Germany , Stockholm, Sweden and 2 more locations